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Juvenile idiopathic arthritis (JIA) differs markedly from adult rheumatoid arthritis. It is not
a single disease, but an exclusion diagnosis that gather together all forms of arthritis that
begin before the age of 16 years, persist for more than 6weeks, and are of unknown
origin. The advent of the new biological treatments has dramatically changed both the
observed responses to treatment and the expectations of therapies. The implementation
of an adequate legislation as well as the presence of international research networks of
pediatric rheumatology have contributed to foster the conduct of controlled clinical trials
and the development of validated outcome measures. This review will currently describe
the methodological approach for performing clinical trials in JIA as well as the current
available drug treatment.
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Juvenile idiopathic arthritis (JIA), with incidence and a prevalence
varying from 2 to 20 and from 16 to 150 per 100,000 respectively
(Ravelli and Martini, 2007; Prakken et al., 2011) is the most com-
mon chronic rheumatic condition in childhood and an important
cause of short and long term disability. It is not a disease, but an
exclusion diagnosis that gather together all forms of arthritis that
begin before the age of 16 years, persist for more than 6weeks, and
are of unknown origin. This heterogeneous group of disorders has
been classiﬁed on clinical and laboratory features to try to identify
homogeneous, mutually exclusives categories (ILAR; Petty et al.,
1998, 2004).
In the past just a few randomized controlled trials (RCT)
were performed in children (Connor, 1999; Ruperto and Mar-
tini, 2000). The situation changed dramatically 10 years ago
thanks to the implementation, both in the US and in Europe,
of an adequate pediatric legislation (Ruperto and Martini, 2000,
2011a; see also the European Medicines Agency, EMA, website at
http://www.ema.europa.eu/) that requires companies who wish to
register a new drug for a given disease to conduct studies also in
children if there is a pediatric counterpart of that disease. Pediatric
rheumatology took quick advantage of this new legislation thanks
to the existence of two large non-for proﬁt networks, the Pedi-
atric Rheumatology International Trials Organization (PRINTO;
Ruperto and Martini, 2004) and the Pediatric Rheumatology Col-
laborative Study Group (PRCSG), covering most of the pediatric
rheumatology centers worldwide.
This review will currently describe the methodological
approach for performing clinical trials in JIA as well as the current
available drug treatments.
CURRENT JIA CLASSIFICATION AND PATHOGENESIS
In the current classiﬁcation (Petty et al., 1998, 2004) some JIA cat-
egories appear to be rather deﬁnite disease entities, while others
still appear to include heterogeneous conditions (Martini, 2003). It
should be noted that the recent view we proposed (see below) that
antinuclear antibody positive patients with early onset arthritis
represent a separate subset has not yet been universally accepted.
In the future gene arrays and cytokine proﬁles analysis in large
cohorts of patients will be presumably provide new insights to
better understand JIA heterogeneity.
Systemic JIA
It is clearly different fromall the other forms of JIA and very similar
to adult-onset Still’s disease. It is characterized by a marked acti-
vation of the innate immune system with high spiking fever and
an important elevation of acute phase reactants. For unknown
reasons about 5–8% of patients develop a life threatening compli-
cation known as macrophage activation syndrome (MAS) which
is a form of hemophagocytic lymphohistiocytosis.
The previous hypothesis of a major pathogenic role of
interleukin-6 (IL6; De Benedetti and Martini, 1998, 2005) has
been conﬁrmed by the efﬁcacy of tocilizumab, an anti-IL6 receptor
antibody (Yokota et al., 2008; De Benedetti et al., 2010). Anti-IL-
1 treatment has also shown to be effective (Pascual et al., 2005).
Moreover, treatment with Anakinra seems to allows to differen-
tiate two subsets of patients (Gattorno et al., 2008) one with
a dramatic response similar to that observed in cryopirin asso-
ciated autoinﬂammatory syndromes (Goldbach-Mansky et al.,
2006; Gattorno et al., 2007) and the other that is resistant or
has an incomplete response (Nigrovic et al., 2011; Quartier et al.,
2011).
The systemic features, the marked activation of the innate
immune system, the lack of any consistent association with
autoantibodies or HLA antigens, and the response to IL-1 inhi-
bition has led to categorize at least some forms of systemic JIA
(sJIA) as autoinﬂammatory diseases.
Children with sJIA are at higher risk of progression to severe
disability (Susic et al., 2011).
Oligoarthritis
The large majority of patients within this category belongs to a
quite well deﬁned disease which is not observed in adults. It is
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characterized by an early onset (before 6 years of age), an asym-
metric arthritis involvingmainly large joints, a female predilection,
a high frequency of positive antinuclear antibodies (ANA), a high
risk for developing chronic iridocyclitis and consistent HLA asso-
ciations. The present classiﬁcation distinguishes two categories of
oligoarthritis based on the number of joints that are involved:
persistent oligoarthritis in which the disease remains conﬁned to
four or less joints and extended oligoarthritis in which arthritis
extend to more than four joints after the ﬁrst 6months of disease
However, ANA positive patients belonging to these two categories
share the same characteristics, strongly suggesting that they repre-
sent the same disease (Ravelli et al., 2005, 2011). Given the good
prognosis a proportion of these children are treated with intra-
articular steroids injections only (Ravelli et al., 2001; Ravelli and
Martini, 2007; Magni-Manzoni et al., 2008; Solari et al., 2008).
Rheumatoid factor negative polyarthritis
It is a heterogeneous JIA category. At least two distinct subsets
can be identiﬁed: (a) a form similar to adult-onset RF-negative
RA and characterized by symmetric synovitis of large and small
joints, onset in school age, and negative ANA; (b) a form that
resembles oligoarthritis, except for the number of joints affected in
the ﬁrst 6months of disease. These similarities led to hypothesize
that this second subset of RF-negative polyarticular JIA and early
onset oligoarthritis are the same disease, the former representing
a rapid arthritis spread in the latter (Martini, 2003). This has been
conﬁrmed by the demonstration that ANA positive oligoarthritis
shares the same features (asymmetric arthritis, early age at onset,
female predominance, elevated incidence of chronic iridocyclitis)
with ANA positive, RF-negative polyarthritis, but not with ANA-
negative RF-negative polyarthritis or ANA-negative oligoarthritis
(Ravelli et al., 2005, 2011). The heterogeneity of RF-polyarticular
JIA has been conﬁrmed also by gene expression studies (Grifﬁn
et al., 2009)Moreover, it has been recently shown that aB cell signa-
ture characterizes patients with early onset arthritis independently
from the number of joints involved (Barnes et al., 2010). For what
concern prognosis it has been reported that an higher degree of
response in the initial 6months of therapy predicts a more favor-
able long term outcome of patients with JIA with polyarticular
course (Bartoli et al., 2008).
Rheumatoid factor positive polyarthritis
It is the same disease as adult rheumatoid factor (RF) positive
rheumatoid arthritis (RA). However, at variance with adult age,
it represent only a small proportion (3–5%) of all JIA cases. For
prognosis it has been reported that children with polyarticular JIA
spent themajority of their follow-upwith active disease; since chil-
dren who were RF positive and with early radiographic evidence
of joint damage tended to have the most active disease, improv-
ing outcomes for these subgroups may be an important goal for
prospective study (Ringold et al., 2009).
Psoriatic arthritis
It also appears to represent a heterogeneous entity (Martini, 2003)
If psoriatic arthritis is deﬁned according to the Vancouver crite-
ria (presence of arthritis and psoriasis or some psoriatic features)
two populations of patients are identiﬁed: (a) one that belong to
the enthesitis related arthritis category and represent therefore,
similarly to adult psoriatic arthritis, a form of spondyloarthropa-
thy; (b) a second form that is very similar to ANA positive
oligoarthritis with only minor differences such as a more frequent
involvement of small joints. Consistently, most patients that meet
the ILAR criteria for psoriatic arthritis, in which patients with
enthesitis are by deﬁnition excluded, have the feature of ANA pos-
itive oligoarthritis (Stoll et al., 2006, 2008). So it appears that the
association of psoriasis with arthritis leads to the identiﬁcation
of two different subsets of patients, one that is similar to adult
psoriatic arthritis and the other that is overlapping, with only
minor differences,withANApositive oligoarthritis (Martini, 2003;
Ravelli et al., 2005).
Enthesitis related arthritis
It is deﬁned by the presence of arthritis and enthesitis. It represent
a form of undifferentiated spondyloarthropathy. Most patients
are HLA-B27 positive and sizable proportion of them develop the
involvement of sacroiliac joints during disease course (Ravelli and
Martini, 2007; Prakken et al., 2011).
Undifferentiated arthritis
It is by deﬁnition heterogeneous since it includes patients who do
not fulﬁll inclusion criteria for any category or fulﬁll the criteria
for more than one category.
HOW TO DEFINE RESPONSE TO THERAPY IN JIA
In 1997, validated criteria to evaluate response to therapy in JIA
were published. These criteria were adopted by the ACR and are
now known as the ACR Pediatric 30 (Giannini et al., 1997). In
addition they are now accepted by both the U.S. Food and Drug
Administration (FDA) and the EMA for all phase II/III trials in
JIA seeking drug registration (Committee for Medicinal Products
for Human Use, 2006).
According to the ACR Pediatric 30, patients are considered
responders to a given therapy if they demonstrate at least 30%
improvement from baseline in at least 3 of any 6 JIA core set
variables, with no more than 1 of the remaining variables wors-
ening by more than 30%. Commonly, patients also are evaluated
for higher level of improvement ACR Pediatric 50, 70, 90, and
100). Variables included in the JIA core set variables include: (1)
the number of joints with active arthritis (Cassidy et al., 1986);
(2) the number of joints with limited range of motion; (3) the
physician’s global assessment of disease activity; (4) the parent
assessment of child’s overall well-being; (5) a validated measure
of functional ability, usually measured by the disability index of
the Childhood Health Assessment Questionnaire (CHAQ; Mar-
tini Ruperto, 2001; Ruperto et al., 2001), or by other instruments
derived from the literature such as the Juvenile Arthritis Multi-
dimensional Assessment Report (JAMAR; Filocamo et al., 2007,
2011); (6) a laboratory measure of inﬂammation, either the ESR
or CRP. For trial in children with sJIA, in addition to the 6 core
variables, the absence of spiking fever (≤38˚C during the week
preceding the evaluation) is an additional requirement.
In addition to the JIA core setmeasures assessment of structural
joint damage is a key outcome required by the FDA for studies in
chronic arthritis, but has never been studied in JIA as part of a clin-
ical development program. Because several reliable radiographic
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scoring systems now are available (Ravelli et al., 1998, 2007; Van
Rossum et al., 2005; Rossi et al., 2006; Malattia et al., 2008; Ravelli,
2008) to properly quantify joint erosions and space narrowing,
this key outcome should be considered in all future JIA trials.
Similarly, the evaluation of the inactive disease status (deﬁned
as no arthritis, no sJIA sign/symptoms, no uveitis, normal index
of inﬂammation, and normal physician’s global assessment of dis-
ease activity, absence of morning stiffness; Wallace et al., 2004) is
an important outcome to be reported in JIA clinical trials. When
the deﬁnition of inactive disease status is met for six continuous
months the patient is said to be in clinical remission on medica-
tion. When the inactive disease status is met for 12months in the
absence of any medication then the patient is classiﬁed as being in
a state of clinical remission off medication.
STUDY DESIGNS IN JIA CLINICAL TRIALS
While a multitude of study designs can be considered (Pocock,
1983), the major trial designs are the classic parallel randomized
clinical trial (RCT) with placebo or active comparator and the ran-
domized withdrawal design. While the parallel design still remain
the gold standard for establishing the efﬁcacy and short-termsafety
of an experimental agent, disadvantages include ethical concerns
due to the use of placebo in children with chronic condition for
which alternative treatments are available. The option of using
an active control is not feasible due to the high sample size that
are required by these kind of trial (Ruperto et al., 2010a). The
double-blind, controlled, randomized withdrawal design was pro-
posed for the ﬁrst time by Dr Lovell and Dr Giannini for use in
pediatric rheumatology studies (Giannini et al., 1996). Eligible
children are treated in an open-label fashion with the experi-
mental therapy to be tested in the trial for a few months after
which responders (typically deﬁned as those demonstrating an
ACR Pediatric 30 response) are randomized in a double-blind
fashion either to continue the experimental therapy or to switch
to placebo. In this segment of the study, called the double-blind
withdrawal phase, patients who demonstrate a pre-deﬁned def-
inition of disease worsening (e.g., “ﬂare”) are withdrawn from
the double-blind withdrawal phase and usually re-treated with
the experimental therapy in an open-label fashion. The with-
drawal design has proven to be very effective design and has been
used in nearly all recent trials of biologic agents in children with
JIA (Lovell et al., 2000, 2008; Ruperto et al., 2008; Yokota et al.,
2008). Data gathered by use of this design led to the approval
of biologic agents for children with JIA by both the FDA and
EMA.
CURRENT EVIDENCE FOR THE TREATMENT OF JIA
In the last decade there has been an important advance in the treat-
ment of JIA mainly due to the available of biologic agents coupled
with the pediatric legislation that has forced many companies to
perform studied in children [Regulation (EC), 2006].
Since there are several JIA categories to be studied most of
the clinical trials described in the following sections employed
the concept of polyarticular course JIA. This functional cate-
gory groups patients with extended oligoarthritis, polyarthritis
RF positive or negative, and systemic arthritis without active sys-
temic features. Speciﬁc studies have been implemented so far only
for sJIA while trials for psoriatic arthritis and enthesitis related
arthritis are currently ongoing.
In the following sections the current evidence about the most
widely used drugs, for children with polyarticular course JIA, is
summarized.
METHOTREXATE
In case of failure of treatment with non-steroidal anti-
inﬂammatory drugs (NSAIDs) and intra-articular steroid injec-
tions with triamcinolone hexacetonide then patients are candidate
to receive methotrexate (MTX; Giannini et al., 1992). Giannini
et al. (1992) established the efﬁcacy of low-dose (10mg/m2) oral
weekly MTX in JIA, later conﬁrmed by another group (Woo
et al., 2000). The maximum effective dose (15mg/m2/week max
20mg/week; Ruperto et al., 2004) was established by the PRINTO
group along. More recently another PRINTO trial showed that in
patients with JIA in remission randomized to withdraw MTX after
6 (early MTX withdrawal) or 12-month (late MTX withdrawal)
there was no statistical signiﬁcant difference in the relapse rate
between the two arms.Howeverwhen the relapse ratewas analyzed
according to the level of MRP8/14 the trial showed that higher
MRP8/14 concentrations (690 ng/mL or greater) were associated
with an higher risk of relapse after discontinuing MTX (Foell et al.,
2010).
ANTI-TUMOR NECROSIS FACTOR AGENTS
Three anti-TNF agents have been so far tested in RCT in pol-
yarticular course JIA and have shown comparable efﬁcacy and
safety.
A controlled trial with a withdrawal design has shown the efﬁ-
cacy of etanercept, at a dose of 0.4mg/kg subcutaneously. twice
a week, in patients with JIA who were resistant or intolerant to
methotrexate (Lovell et al., 2000). Etanercept has been the ﬁrst
biological agent registered for use in JIA and subsequently, other
studies have conﬁrmed the remarkable and rapid efﬁcacy and the
good safety proﬁle of the drug in JIA. The German registry, using
theACRPedi 30 criteria of 30, 50, and 70% improvement, reported
a therapeutic response in JIA patients in, respectively, 66, 54, and
30% after 1month, 78, 61, and 38% after 3months, and 83, 72, and
52% after 6months with a good overall tolerability (Horneff et al.,
2004). According to the Dutch registry 77% met the criteria of
the ACR Pedi 30 in the ﬁrst 3months of treatment; for the major-
ity of patients this improvement was sustained and 53 (36%) of
all patients met the remission criteria. (Prince et al., 2009) More
recently Giannini et al. (2010) showed that etanercept treatment,
with or without methotrexate, may contribute to the restoration
of normal growth in children with JIA.
A controlled trial with MTX plus either inﬂiximab or placebo
failed to demonstrate a statistically signiﬁcant difference in its pri-
mary outcome (ACRPedi30) probably because of the very high
placebo response rate (Ruperto et al., 2007). However, by week
52, ACR Pedi50 and ACR Pedi70 responses were attained in
69.6 and 51.8% of patients respectively, values similar to those
observed with etanercept. Of note, although the two dosages used
(3 and 6mg/kg) were of comparable efﬁcacy, patients receiving
3mg/kghad amore frequent occurrences of serious adverse events,
infusion reactions, antibodies to inﬂiximab, and newly induced
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antinuclear and anti- double-stranded DNA antibodies. There-
fore, 6mg/kg is the dose recommended in pediatric rheumatology
practice. Safety and efﬁcacy were also conﬁrmed in an open-label
long term extension study (Ruperto et al., 2010b). Inﬂiximab is
not registered for use in JIA.
A controlled trial with a withdrawal design has shown the efﬁ-
cacy also of adalimumab (Lovell et al., 2008). Patients enrolled in
this trial, eitherMTXnaive orMTXresistant or intolerant, received
24mg/m2 of adalimumab (maximum dose 40mg). Seventy-four
percent of patients not receiving methotrexate and 94% of those
receiving methotrexate had an ACR Pedi 30 response at week 16
and were eligible for double-blind treatment. At 48weeks, the per-
centages of patients treated with methotrexate who had ACR Pedi
30, 50, 70, or 90 responses were signiﬁcantly greater for those
receiving adalimumab than for those receiving placebo; response
rates were sustained after 104weeks of treatment. Overall, safety
and efﬁcacy were comparable to those observed with the other
anti-TNF agents. Adalimumab is registered for JIA in both USA
and Europe.
Other anti-TNF agents such as golimumab (see http://clinicaltri
als.gov/) are undergoing phase III trial while for others such as
certolizumab there are not yet public information available.
Although no speciﬁc studies exists in children the results of the
adalimumab trial as well as a retrospective analysis of the German
registry (Horneff et al., 2009) suggest that also in children anti-
TNF agents are more effective if combined with MTX. Similarly,
no studies have been devised to assess the diseasemodifying poten-
tial of biological agents on disease progression in JIA although a
retrospective analysis has suggested that etanercept may reduce
radiographic progression (Nielsen et al., 2008).
Overall, the safety of anti-TNF agents has proven to be good
also in children with a low rate of serious infections (Hashkes
et al., 2010). The only exception is a possible, small increased
risk of lymphoma and other types of cancers in children as
reported by the FDA’s Adverse Events Reporting System (AERS;
Diak et al., 2010). However, a clear causal relationship cannot
be established due to the concomitant use of immunosuppres-
sive drugs and the lack of reliable information on the potential
risk of malignancy in JIA alone or treated with MTX. Of note,
recently, Simard et al. (2010) did not found an increased risk
of cancer occurrence from 1969 through 2007, in a nationwide
Swedish population-based cohort of 9,020 JIA children matched
with ﬁve general-population comparators (n = 44,858). However,
when the analysis was restricted to the JIA cases diagnosed since
1987, the relative risk increased to 2.3 for all malignancies and to
4.2 for lymphoproliferative malignancies. The increase could not
be explained by the introduction of biological therapies because
the association was similar in analyses ending in 1999. In this
respect it has been pointed out that 1986 was the year in which
the ﬁrst report for the use of methotrexate in JIA was pub-
lished (Ruperto and Martini, 2011b). Several other publications
are available on the topic of malignancies in JIA (Bernatsky et al.,
2011; Horneff et al., 2011). To answer the important question
of a potential increase of cancer in children with JIA treated
with MTX and/or with biological agents a proper active phar-
macovigilance system with very large sample size and an adequate
follow-up is needed. Such a registry is going to be implemented,
thanks to the support of the European Union, by a joint effort
of the Pediatric Rheumatology European Society (PRES) and the
PRINTO.
ABATACEPT
Abatacept is another biological agent that has been registered for
use in JIA. Its efﬁcacy has been shown in a double-blind random-
ized controlled withdrawal trial in 190 patients with polyarticular
course JIA and inadequate response or intolerance to at least one
DMARD, including anti-TNFdrugs (Ruperto et al., 2008). Patients
were given 10mg/kg of abatacept intravenously every 28 days in
the open-label period of 4months and subsequently randomized
in a double-blind fashion to receive either placebo or abatacept.
Sixty-seven per cent of patients showed an ACR Pedi30 response.
ACR Pedi50, Pedi70, and Pedi90 response rates were 50, 28, and
13%, respectively, while 13% of patients had inactive disease after
the lead-in phase. Among patients who previously failed an anti-
TNF agent 39 and 25% had, respectively, an ACR Pedi 30 and 50
response. Treatment was well tolerated and accompanied by a sig-
niﬁcant improvement in health-related quality of life (HRQOL;
Ruperto et al., 2010c). Of the 190 enrolled patients, 153 entered
a long term open-label extension (LTE) phase that conﬁrmed
the efﬁcacy and safety of abatacept and suggested a durable efﬁ-
cacy also in patients who did not initially achieve an ACR Pedi
30 response during the initial 4-month open-label lead-in phase
(Ruperto et al., 2010d).
OTHER BIOLOGICAL AGENTS
Systemic JIA is clearly different from all the other forms of JIA
and anti-TNF agents have been shown to be less effective in this
JIA subset. In sJIA a controlledwithdrawal trial and several uncon-
trolled studies have shown the efﬁcacy of tocilizumab (Yokota et al.,
2008) and anakinra (Pascual et al., 2005; Gattorno et al., 2008)
respectively. A conﬁrmatory controlled trial with tocilizumab
against placebo has just been completed (De Benedetti et al.,
2010) in sJIA with or without systemic features and another trial
with canakinumab (a monoclonal antibody against IL-1) in chil-
dren with sJIA with active systemic features is ongoing (Ruperto
et al., 2011). It has been hypothesized that a precocious treatment
with anakinra could by associated with a substantial prevention of
refractory arthritis. This hypothesis needs to be substantiated by
prospective randomized trials (Nigrovic et al., 2011).
A controlled study is ongoing to assess the efﬁcacy and the
safety of tocilizumab in polyarticular course JIA.
Rilonacept is a recombinant fusionproteinof IL-1 receptor pro-
tein components and the Fc portion of a human immunoglobulin
administered once weekly by subcutaneous injection. Preliminary
results of a phase II trial showed that among 21 children on rilona-
cept at 2.2–4.4mg/kg/week 10 (47%) patients achieved an ACR 70
response at 42weeks (Hayward and Wallace, 2009).
SAFETY OF BIOLOGIC AGENTS
A thorough review of the side effects of biologic therapy has been
recently reported by Hashkes et al. (2010). In particular in 2008
the FDA issued an early communication (e.g., black box warn-
ing; FDA, 2008) about a possible association between the use
of TNF blockers and the development of lymphoma and other
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cancers in children and young adults with JIA, Crohn’s disease,
or other diseases. These observation were substantiated later by
several Authors. Diak et al. (2010) reported about their search
in the FDA AERS to identify malignancies associated with the
use of anti-TNF blockers (inﬂiximab, etanercept, adalimumab)
in children and concluded that: “There is evidence that treat-
ment with TNF blockers may increase the risk of malignancy.
However, the cases, were confounded by the potential risk of
malignancy associated with the underlying illnesses and the use of
concomitant immunosuppressants; therefore, a clear causal rela-
tionship could not be established.” More recently, Simard et al.
(2010) evaluated the risk of cancer occurrence and vital status
from 1969 through 2007, in a nationwide Swedish population-
based cohort of 9,020 JIA children matched with ﬁve general-
population comparators (n = 44,858). The Authors concluded
that “Though absolute risk are low, we found an elevated risk
of malignancy among biologic-naïve patient with JIA identiﬁed
during the recent 20 years that may have implications on the inter-
pretation of cancer signals in patient with JIA treated with newer
therapies.”
Despite an advance in the understanding of the possible link
between disease, treatment, and cancer occurrence several prob-
lems still remain. To answer these doubts a proper active phar-
macovigilance system with very large sample size and an adequate
follow-up is needed. Currently, thank to the support of the Euro-
pean Union, the PRES (principal investigator N Wulffraat), with
the technical help of the PRINTO (Ruperto and Martini, 2004) is
setting up a projectwith the goal to collectworldwide prevalent (all
patients under treatment or previously treated with methotrex-
ate± biologics) and incident case (all cases newly treated with
methotrexate± biologics) of JIA children. If successful this reg-
istry could be able to tell us if there is an increased the inci-
dence of cancer or any other serious adverse events in children
with JIA.
THE ACR RECOMMENDATION FOR THE TREATMENT OF JIA
Recently theACR has issued recommendation for the treatment of
JIA (Beukelman et al., 2011a,b) based or theRAND/UCLAmethod
(Fitch et al., 2000). Recommendation are based on a step up
approach which require the subsequent use of drugs with greater
power once the previous treatment(s) failed. Recommendation
are proposed for ﬁve functional categories of JIA (see below) and
according to the level of disease activity (low, moderate, and high)
and the presence of poor prognostic features speciﬁc for each JIA
group. In addition the recommendation provide guidance for the
safety monitoring of NSAID, methotrexate (MTX) and TNF-α
inhibitors.
The ﬁrst functional group is related to JIA children with an
history of arthritis in four or less joints during the entire course of
the disease that should be treated primarily with steroid (triamci-
nolone hexacetonide) joint injection(s)±NSAID. If steroid injec-
tions are not sufﬁcient then MTX or sulfasalazine for enthesitis
related JIA, and then TNF-α inhibitors.
The second functional group is related to JIA children with an
history of arthritis in ﬁve or more joints. These patients should
be treated with MTX (or leﬂunomide) and in case of failure with
TNF-α inhibitors. In case of TNF-α inhibitor failure another anti-
TNF-α should be tried or a drug with a different mechanism of
action such as abatacept. This is the group of patients for which
the evidence from the literature is high coming mainly from phase
III randomized clinical trials.
The third functional group is related to JIA children with active
sacro-ileitis. These patients, based on the level of disease activity
and prognostic factors should be treated with NSAIDs, followed
by MTX or sulfasalazine and then, in case of failure with TNF-α
inhibitors.
The fourth group regards children with sJIA and active sys-
temic symptoms that required the use of NSAID with systemic
glucocorticoids and in case of failure anakinra.
The ﬁfth group regards children with sJIA and active arthritis
for which MTX is indicated ﬁrst, followed by TNF-α inhibitors or
anakinra.
Of note for the group of sJIA the recommendations do not
take into account the last evidence related to use of drugs such
as tocilizumab and canakinumab whose information were not
available (Ruperto et al., 2011; De Benedetti et al., 2010).
CONCLUSION
In the last 10 years the implementation of an adequate legislation
fostering controlled clinical trials in children and the availability
of new potent medications such as the biological agents have led
to a dramatic improvement in the treatment of JIA. Despite these
progresses there are still problems to be solved to better under-
stand data related to the long term safety of the drugs as well as to
provide more efﬁcacious treatments for those patients that fail to
adequately respond to current therapies.
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